Boundless Bio (BOLD)

• Market cap: $26.2M
• 1 day: -3.42%
• 5 days: -1.74%
• 1 month: -11.02%
• 3 months: -13.08%
• 6 months: -38.59%
• Year to date: -58.61%
• 1 year: -71.25%
• 5 years: -92.07%
• 10 years: -92.07%
• Sector: Healthcare
• Industry: Biotechnology

About: Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Employees: 64

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

20% less funds holding

Funds holding: 54 [Q1] → 43 (-11) [Q2]

32.53% less ownership

Funds ownership: 76.11% [Q1] → 43.58% (-32.53%) [Q2]

48% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 21

68% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 19

98% less capital invested

Capital invested by funds: $419M [Q1] → $9.85M (-$409M) [Q2]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 165% upside
• Avg. target: $4 254% upside
• High target: $5 342% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

HC Wainwright & Co. Mitchell S. Kapoor	254% upside $4	Buy Maintained	11 Aug 2025
HC Wainwright & Co. Mitchell Kapoor	342% upside $5	Buy Initiated	2 Jun 2025
Leerink Partners Michael Cherny	165% upside $3	Market Perform Downgraded	28 May 2025